EpiCast Report: Renal Cell Carcinoma – Epidemiology Forecast to 2023
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, being responsible for approximately 90% of all cases in adults. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension, night sweats, and a general feeling of being unwell. Kidney cancer is among the 10 most frequently occurring cancers in Western countries. Globally, about 270,000 cases of kidney cancer are diagnosed yearly, and 116,000 people die from the disease.
GlobalData epidemiologists forecast an increase in the diagnosed incident cases of RCC in the 8MM, from 190,147 diagnosed incident cases in 2013 to 309,734 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 6.29% during the forecast period. In 2023, urban China will have the highest number of diagnosed incident cases of RCC in the 8MM, with 147,457 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of RCC, with 7,591 diagnosed incident cases. Similarly, as shown in the second figure below, the five-year diagnosed prevalent cases of RCC in the 8MM will increase from 600,261 diagnosed prevalent cases in 2013 to 966,190 diagnosed prevalent cases in 2023, with an AGR of 6.10% during the forecast period. The increase in the diagnosed five-year prevalent cases of RCC is partly attributed to the rising trend in the incidence rate of RCC in the 8MM, combined with changes in the population demographics in the respective markets.The rising trend in the incidence of RCC may partly be a result of increased use of imaging techniques that can detect asymptomatic tumors.
Scope
The Renal cell carcinoma (RCC) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for RCC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC, segmented by age (at 20-year intervals, starting at age 20 years and ending at ages =80 years) and sex. It also includes a forecast of the five-year diagnosed prevalent cases of RCC in the 8MM. Additionally, it provides the RCC diagnosed incident cases, segmented by the stage at diagnosis, for the 8MM..
The RCC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.